Inspire Medical Systems (INSP) Earnings Date & Reports
Inspire Medical Systems Inc operates as a medical technology company... Show more
INSP is expected to report earnings to fall 339.20% to -23 cents per share on August 04
Inspire Medical Systems (INSP) Q1 2026 Earnings Recap: Beats Estimates but Cuts Guidance
Key Takeaways
- Inspire Medical Systems reported Q1 2026 revenue of $204.6 million, up 1.6% year-over-year and beating consensus estimates of approximately $200 million.
- GAAP diluted EPS was $(0.39), compared to $0.10 last year, while adjusted diluted EPS of $0.10 beat expectations of a loss around $(0.26) to $(0.36).
- Gross margin expanded 180 basis points to 86.5%, driven by higher sales of the higher-margin Inspire V system.
- Operating cash flow improved to $12.8 million from a $6.7 million use last year; cash position at $399.7 million.
- Full-year 2026 guidance lowered to revenue of $825-$875 million (down 4-10% from 2025), citing coding/reimbursement issues and WISeR (Wasteful and Inappropriate Service Reduction) program impacts estimated at $120-$150 million.
- Stock fell over 16% post-earnings amid guidance cut, despite quarterly beats.
Earnings Context and Why It Matters
Inspire Medical Systems, a leader in neurostimulation therapy for obstructive sleep apnea (OSA), faced heightened scrutiny entering Q1 2026 amid ongoing reimbursement uncertainties for its next-generation Inspire V system. The quarter tested the company's resilience against coding changes—where a prior CPT code used for about 10,000 Medicare cases in 2025 became unavailable—and the rollout of the federal WISeR prior-authorization program. These headwinds disrupted procedures, but Inspire delivered revenue growth and margin expansion. For investors, this report highlights execution amid regulatory pressures in the medtech sector, where OSA treatments represent a growing $50 billion addressable market. Strong cash flow and a debt-free balance sheet provide a buffer, but guidance revisions signal near-term challenges in a competitive landscape.
For the first quarter ended March 31, 2026—the company's standard calendar Q1—Inspire reported revenue of $204.6 million, a 1.6% increase from $201.3 million in Q1 2025. This topped consensus expectations of around $200 million, driven by deeper market penetration and adoption of Inspire V, though offset by reimbursement disruptions estimated to shave $20 million from the quarter.
GAAP gross margin rose 180 basis points (bps) to 86.5%, reflecting a favorable product mix with more Inspire V sales, which carry higher margins than the Inspire IV predecessor. Operating expenses grew 3.4% to $178.0 million due to marketing, legal, and employee costs, leading to a narrower operating loss of $1.1 million (margin -0.5%) versus $1.5 million last year. Adjusted operating income was $0.3 million.
Net loss totaled $11.3 million, or GAAP diluted EPS of $(0.39), versus net income of $3.0 million, or $0.10, in the prior year. The swing stemmed partly from a 571.2% effective tax rate due to stock-based compensation shortfalls amid a declining stock price. Adjusted net earnings were $2.8 million, yielding adjusted diluted EPS of $0.10—well above forecasts of a $(0.26) to $(0.36) loss. Operating cash flow flipped to $12.8 million provided, aided by better working capital management.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions in dynamic markets like medtech.
Market Reaction and Investor Sentiment
Despite beating Q1 revenue and adjusted EPS estimates, INSP shares plunged over 16% in the immediate aftermath, trading around $45-46 from a $54.84 close on May 4, 2026. The sharp decline reflected investor disappointment with the lowered full-year outlook, overshadowing quarterly positives. Sentiment soured on persistent reimbursement risks and WISeR impacts, with analysts noting the $120-$150 million full-year drag as a key concern. Pre-earnings, expectations centered on potential weakness from these issues, but the guidance cut amplified fears of prolonged pressure.
Forward Outlook and Key Factors to Monitor
Inspire narrowed its 2026 revenue guidance to $825-$875 million, implying a 4-10% decline from 2025's approximately $912 million, down from prior expectations of $950 million-$1 billion. Adjusted operating margin is now seen at 2-4%, with GAAP diluted EPS at $0.07-$0.62 and adjusted at $0.75-$1.25. This assumes a 65-70% effective tax rate, 29.4 million weighted average diluted shares, and $40-$45 million in capital expenditures. Management attributes the revision to ongoing coding uncertainty for Inspire V Medicare cases and WISeR prior authorizations, projecting a $120-$150 million total hit, with Q2 revenue down 9-11% and an adjusted operating loss of $10-$15 million.
CEO Tim Herbert emphasized these as temporary challenges, with solutions in progress alongside stakeholders. The company expects a return to growth in 2027, fueled by Inspire V's clinical advantages, including simplified procedures and superior outcomes in OSA therapy.
Investors should track progress on coding resolutions, WISeR adaptation, Inspire V adoption rates, and physician reimbursement trends. Gross margin trajectory, cash generation (bolstered by $399.7 million in cash/investments), and R&D updates on next innovations will also be critical amid medtech reimbursement dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a developer of implantable neurostimulation systems to treat obstructive sleep apnea
Industry MedicalNursingServices